Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.49 |
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3608311 | 1.00 | SIGMAR1 (0.51) | SIGMAR1HRH3KDM1AMAOBHDAC1 | |
| SCHEMBL3604553 | 0.91 | HRH3 (0.55) | SIGMAR1HRH3KDM1AMAOBHDAC1 | |
| SCHEMBL3596794 | 0.91 | HRH3 (0.55) | SIGMAR1HRH3KDM1AMAOBHDAC1 | |
| SCHEMBL3601711 | 0.91 | HRH3 (0.55) | SIGMAR1HRH3KDM1AMAOBHDAC1 | |
| Trifluoroacetic Acid SCHEMBL3610726 | 0.84 | KDM1A (0.48) | KDM1AMAOBNPC1 | |
| Trifluoroacetic Acid SCHEMBL3610727 | 0.84 | KDM1A (0.48) | KDM1AMAOBNPC1 | |
| Trifluoroacetic Acid SCHEMBL3601568 | 0.82 | KDM1A (0.41) | KDM1AMAOBNPC1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL3601567 | 0.82 | KDM1A (0.41) | KDM1AMAOBNPC1SMN1; SMN2 | |
| SCHEMBL3600203 | 0.80 | KDM1A (0.49) | KDM1AMAOBNPC1 | |
| SCHEMBL3605976 | 0.80 | KDM1A (0.49) | KDM1AMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121612-B1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-10-01 | — | — | EP | disclosed |
| US-8299102-B2 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-1942104-A1 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | PTGIS, TBXAS1, EDNRA | SIGMAR1 1201/4885HRH3 117/4885KDM1A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.